Trial Profile
A prospective, multi-centre, observational study to investigate real world patterns of docetaxel use for metastatic castration-resistant prostate cancer (mCRPC) in china
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2017
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress